Scientific paper

Epoxy Functionalized Carboxymethyl Dextran Magnetic Nanoparticles for Immobilization of Alcohol Dehydrogenase

Katja Vasić,¹ Željko Knez,^{1,2} Sanjay Kumar,³ Jitendra K. Pandey⁴
and Maja Leitgeb^{1,2*}

¹ University of Maribor, Faculty of Chemistry and Chemical Engineering, Smetanova 17, SI-2000 Maribor, Slovenia, phone: +386 2 2294 462, e-mail: maja.leitgeb@um.si

² University of Maribor, Faculty of Medicine, Taborska ulica 8, SI-2000 Maribor, Slovenia

³ University of Petroleum and Energy Studies, Department of Chemistry, Dehradun, Uttarakhand, India

⁴ University of Petroleum and Energy Studies, Research and Developments, Dehradun, Uttarakhand, India

* Corresponding author: E-mail: maja.leitgeb@um.si

Received: 04-25-2020

Abstract

Microbial inhibition of carboxymethyl dextran (CMD) magnetic nanoparticles (MNPs) was investigated on two different bacterial cultures, *Escherichia coli* and *Staphylococcus aureus*, where inhibition properties of CMD-MNPs were confirmed, while uncoated MNPs exhibited no inhibition properties. To such CMD-MNPs, enzyme alcohol dehydrogenase (ADH) from *Saccharomyces cerevisiae* was immobilized. Later on, CMD-MNPs were functionalized, using an epoxide cross-linker epichlorohydrin (ECH) for another option of ADH immobilization. Residual activities of immobilized ADH onto epoxy functionalized and non-functionalized CMD-MNPs were determined. Effect of cross-linker concentration, temperature of immobilization and enzyme concentration on residual activities of immobilized ADH were determined, as well. With optimal process conditions (4% (v/v) ECH, 4 °C and 0.02 mg/mL of ADH), residual activity of immobilized ADH was 90%. Such immobilized ADH was characterized using FT-IR, SEM and DLS analysis.

Keywords: Alcohol dehydrogenase, carboxymethyl dextran, epoxy functionalization, epichlorohydrin, enzyme activity

1. Introduction

As versatile and efficient enzyme, alcohol dehydrogenases (ADH) has always had an important role in modern green chemistry, especially since it can perform selective oxidations and reductions.^{1,2} ADHs have many applications in production of various intermediates in chemical industries, such as production of chiral compounds, regeneration of different cofactors and in biosensors.^{3–6} However, poor stability presents a limitation in the industrial use of ADH and many strategies have been developed to improve and increase its stability. These methods include protein engineering, chemical modification and most commonly used immobilization.^{7–11}

Iron oxide nanoparticles are often used as nanocarriers for enzyme immobilization and present a promising

tool in various medical fields, which has numerous clinical applications, such as targeted drug delivery, cell labelling, tissue repairment and various applications in biosensors.^{12–16} Magnetic nanoparticles (MNPs) have unique properties, such as superparamagnetism, large surface area and low toxicity.^{17–19} However, they are inclined to aggregate, because of their strong magnetic dipole.^{20,21} To avoid such aggregation, modification of nanoparticles is in place. In our study, we used organic polymer carboxymethyl dextran (CMD) to provide better biocompatibility and biodegradability with low toxicity of synthesized MNPs.^{22–25}

Modified MNPs are usually further functionalized using different functionalization groups. Epoxy functional group is a very active group, which can react with proteins, enzymes and nucleic acids, resulting in beneficial immobilization of biomolecules. Epoxy groups are also very stable

at neutral pH values, therefore different commercial supports can be prepared at a far position, where the enzyme has to be immobilized, which means epoxy-activated supports are very suitable biological systems to develop easy enzyme immobilization protocols.^{26,27} ECIH is an epoxide with bifunctional alkylating activity and is routinely used in the production of numerous synthetic materials, including epoxy, phenoxy and polyamide resins, cross-linked starch, surfactants and many pharmaceutical products.²⁸ There are studies describing epoxy-functionalized nanoparticles, modified with silica, as a carrier for immobilization of ADH from horse liver to be a suitable support for immobilization of ADH,^{29,30} and studies reporting of immobilization of lipase and laccase covalently immobilized on magnetic microspheres, silica nanoparticles or chitosan magnetic beads via active epoxy groups.^{31–33} All reported studies show the importance and significance of epoxy-functionalized nanoparticles, suitable for enzyme immobilization.

As there are many research studies investigating immobilization of ADH onto different magnetic supports, there are none that report about immobilization of ADH onto functionalized CMD-MNPs, using epichlorohydrin as an epoxide cross-linker. In our study, effect of process parameters was investigated, such as cross-linker concentration, temperature of immobilization and enzyme concentration to obtain the highest residual activity of immobilized ADH. Additionally, characterization of such immobilized ADH was performed using FT-IR, SEM and DLS analysis.

2. Materials and Methods

2.1. Materials

CMD sodium salt, sodium phosphate, sodium pyrophosphate, ECIH (1-Chloro-2,3-epoxypropane), ethanol, β -nicotinamide adenine dinucleotide (β -NAD) and ADH from *S. cerevisiae* were purchased from Sigma-Aldrich. Iron (III) chloride hexahydrate ($\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$), iron (II) chloride tetrahydrate ($\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$), Coomassie brilliant blue, Peptone from meat, Meat extract, agar, Yeast extract and Tryptic soy broth were obtained from Merck. Ammonium hydroxide was purchased from Chem-Lab, Belgium. All reagents in this work were of analytical purity and used without further purification. In all experiments, deionized water was used.

2.2. Methods

2.2.1. Synthesis and Toxicity of CMD-MNPs

CMD-MNPs were prepared by protocol developed in our previous research, published by Vasić et al.³⁴ Further we wanted to investigate the toxicity of the prepared CMD-MNPs. This was tested on two different bacterial cultures, Gram negative *E. coli* and Gram positive *S. au-*

Table 1. Growth media for *E. coli* and *S. aureus*

<i>E. coli</i>		<i>S. aureus</i>	
Peptone from meat	5 g	Tryptic Soy Broth	30 g
Meat extract	3 g	Yeast extract	3 g
Agar	15 g	Agar	15 g
Distilled H ₂ O	1 L	Distilled H ₂ O	1 L

reus. Growth media for both bacterial cultures was prepared according to Table 1, later on sterilized and prepared as growth medium in a petri dish. *E. coli* and *S. aureus* with concentration of 10^5 CFU/mL were smeared on a petri dish, to which 10–30 mg of CMD-MNPs was added. Petri dishes with culture *E. coli* and *S. aureus*, together with CMD-MNPs, were incubated at 37 °C for 24 hours.

2.2.2. Immobilization of ADH Onto CMD-MNPs

To CMD-MNPs, ADH and sodium acetate buffer (10 mM) were added with a volumetric ratio 1:9. Final ADH concentration in the reaction mixture was 0.02 mg/mL. Immobilization was carried out for 2 hours at 4 °C and 22 °C, with 500 rpm.

2.2.3. Epoxy Functionalization of CMD-MNPs

CMD-MNPs were functionalized with 4 % (v/v) ECIH (0.5 M) in 10 mM sodium acetate buffer, pH 7.5. Functionalization was carried out with continuous mixing for 1 hour at 300 rpm and 22 °C. After functionalization, the supernatant was removed and epoxy functionalized CMD-MNPs were obtained.

2.2.4. Immobilization of ADH Onto Epoxy Functionalized CMD-MNPs

To epoxy functionalized CMD-MNPs, ADH and sodium acetate buffer (10 mM) were added with a volumetric ratio 1:9. Final ADH concentration in the reaction mixture was 0.02 mg/mL. Immobilization was carried out for 2 hours at 4 °C and 22 °C, with 500 rpm.

2.2.5. Assay for ADH Activity

The activity of soluble and immobilized ADH was determined spectrophotometrically using ethanol as a substrate. The standard reaction mixture in a total volume of 3 mL contained 22 mM sodium pyrophosphate, 3.2% (v/v) ethanol, 7.5 mM β -NAD, 0.3 mM sodium phosphate and 0.003 (w/v) % BSA. The reaction was initiated by the addition of ethanol and β -NAD to soluble or immobilized ADH, and subsequently the increase in absorbance at 340 nm due to formation of β -NADH was measured.

The activity of soluble and immobilized ADH was calculated using the following equation:

$$\frac{\text{Units}}{\text{mL}} \text{ enzyme} = \frac{((\Delta A_{340 \text{ nm}} / \text{min}) \text{ of SAMPLE} - (\Delta A_{340 \text{ nm}} / \text{min}) \text{ of BLANK}) * 3 * df}{6.22 * 0.1} \quad (1)$$

where:

- 3 – total volume (mL) of assay
- df – dilution factor
- 6.22 – millimolar extinction coefficient of β -NADH at 340 nm
- 0.1 – volume (mL) of enzyme used

Enzymatic activity of ADH was measured in triplicates by enzymatic assay for ADH by Sigma-Aldrich protocol,³⁵ and the residual activity was calculated from the following equation:

$$\text{Residual activity (\%)} = \frac{\text{activity of immobilized ADH}}{\text{activity of soluble ADH}} * 100 \quad (2)$$

2. 2. 6. Protein amount determination and immobilization efficiency calculation

The protein amount of non-immobilized and immobilized ADH was determined by measuring the protein concentration by Bradford method using Bovine serum albumin (BSA) as a standard.³⁶ The amount of ADH immobilized on the surface of CMD-MNPs was determined on the basis of the protein amount in supernatant fraction (c_s) and later calculated by subtracting the measured amount (c_s) from the amount of non-immobilized ADH (c_e).

Immobilization efficiency was calculated using the following equation:

$$\text{Immobilization efficiency (\%)} = \frac{c_e - c_s}{c_e} * 100 \quad (3)$$

where:

- c_s – protein concentration in supernatant fraction of immobilized ADH
- c_e – protein concentration of non-immobilized ADH

All measurements for activity and protein amount determination were performed in triplicates and exhibited a standard deviation of less than 2%.

2. 3. Characterization

2. 3. 1. FT-IR

FT-IR spectra were recorded to study chemical bonds formed between ADH immobilized CMD-MNPs. FT-IR analysis of the samples was performed by pressing the samples to form a tablet using KBr as the matrix. The spectra were detected over a range of 4000–500 cm^{-1} and recorded by a FT-IR spectrophotometer (Perkin Elmer 1600 Fourier transform infrared spectroscopy spectrophotometer).

2. 3. 2. SEM

The morphology and size of CMD-MNPs and ADH-CMD-MNPs was investigated by SEM analysis using a scanning electron microscope (FE, SEM SIRION, 400 NC, FEI). The samples were measured on a gold (Au) substrate.

2. 3. 3. DLS

The particle size distribution, hydrodynamic size and ζ -potentials of the samples were measured using DLS (Zetasizer Nano ZS). Each diameter value was the average of three consecutive measurements. Higher values indicate a very broad size distribution, whereas lower values correspond to more or less monodisperse particle size distributions. Measurements were carried out under equilibrium conditions. Measured samples were dispersed in water with neutral pH at room temperature. Concentration of all CMD-MNPs and ADH-CMD-MNPs were 2 mg/mL.

3. Results and Discussion

3. 1. Toxicity of CMD-MNPs

Inhibition properties of synthesized CMD-MNPs on the growth of bacterial cultures *E. coli* and *S. aureus* were investigated, compared to uncoated magnetic nanoparticles. Qualitative assessment of inhibition properties was determined after incubation for 24 hours at 37 °C. If the

Figure 1. Uncoated MNPs on bacterial culture *E. coli* after incubation at 37 °C for 24 hours (a), CMD-MNPs on bacterial culture *E. coli* after incubation at 37 °C for 24 hours, where inhibition zone can be seen (b), uncoated MNPs on bacterial culture *S. aureus* after incubation at 37 °C for 24 hours (c) and CMD-MNPs on bacterial culture *S. aureus* after incubation at 37 °C for 24 hours, where inhibition zone can be seen (d).

inhibition zone was present, additional quantitative assessment was performed. **Figure 1** shows that inhibition occurs when CMD-MNPs were incubated with both bacterial cultures, while uncoated MNPs exhibited no inhibition properties. Additional quantitative assessment revealed that the average inhibition zone was 19.7 mm when incubated with *E. coli* and 19 mm, when incubated with *S. aureus*. CMD-MNPs exhibit antibacterial properties, since they are modified with organic polymer CMD. The modification of MNPs with organic polymers makes MNPs biocompatible, biodegradable and mostly non-toxic, which is a favourable advantage with using suitable support for immobilization of enzymes.^{17,18,37}

3. 2. ADH Immobilization

ADH was immobilized onto CMD-MNPs, which were not epoxy functionalized and onto epoxy functionalized CMD-MNPs at two different immobilization temperatures, 4 °C and 22 °C. As seen from **Figure 2a**, residual activities increased drastically, when ADH was immobilized onto epoxy functionalized CMD-MNPs. Residual activity at 22 °C increased from 15% to 39%, while at 4 °C it increased even more, from 26% to 87%. Results suggest that epoxy functionalized CMD-MNPs ensure more successful immobilization of ADH onto the surface of the carrier, since the functionalization of CMD-MNPs provides additional epoxy functional groups, to which the amino groups of the enzyme can bind.

Further, we the influence of cross-linker concentration on the residual ADH activity was studied. The concentration of ECIH was optimized by performing immobilization of ADH onto CMD-MNPs with different volumetric ratios of 0.5 M ECIH as a cross-linking reagent. Enzyme residual activity was determined with the help of enzymatic assay for ADH determination, using ethanol as

a substrate and immobilization efficiency was determined with the help of estimating the protein concentration with Bradford method in supernatants after immobilization and 2 times washing of the immobilized ADH-CMD-MNPs. As shown in **Figure 2b**, when applying 2% (v/v) of ECIH, the residual activity was very low, only 19%, which could suggest that low cross-linker concentration gives poor mechanism strength, easily leading to leaching of the enzyme from carrier support. By doubling the concentration of cross-linker ECIH to 4% (v/v), the residual activity started to increase and was found to be optimal volumetric concentration, since it retained 88% of the original enzyme activity. With increasing cross-linker concentration, the amount of free active groups on the surface of the carrier resulted in higher ADH loading, causing higher residual activity of immobilized ADH. Also, immobilization efficiency was very high, resulting in 100%. In this case, immobilization efficiency goes hand-in-hand with the residual activity of ADH. With doubling the concentration of cross-linker ECIH again, to 8% (v/v), residual activity and enzyme immobilization efficiency started to decrease. The significant residual activity decrease to 21% at 8% (v/v) of ECIH suggests that the limit of cross-linking was reached. Too high concentration of cross-linker can result in enzyme deactivation on one hand and on the other hand the loss of activity happens because access concen-

Table 1. Residual activities and immobilization efficiency of ADH immobilized onto epoxy functionalized CMD-MNPs, while investigating time of immobilization.

Time of immobilization [h]	Residual activity [%]	Immobilization efficiency [%]
2	87	100
12	37	96

Figure 2. Residual activities of ADH immobilized onto CMD-MNPs, while investigating temperature of immobilization with and without epoxy functionalization (a) and cross-linker concentration (b).

trations of cross-linker result in blocking of enzyme active groups.³⁸ Immobilization efficiency was 89% for 8% (v/v) and 94% for 2% (v/v) of used ECLH.

The influence of immobilization time is presented in **Table 1**. At first, immobilization time was investigated at 2 hours, and later on prolonged to 12 hours. When performing immobilization for 2 hours, residual activity of immobilized ADH-CMD-MNPs of 87% with 100% immobilization efficiency was achieved. When the immobilization time was prolonged to 12 hours, the residual activity of immobilized ADH-CMD-MNPs decreased drastically, to 37% with 96% immobilization efficiency. The results indicate that the immobilization time has an important effect on residual activity of immobilized ADH-CMD-MNPs and that the optimal immobilization lasts for 2 hours, which is sufficient time to bind enzyme ADH effectively to CMD-MNPs surface with its highest possible activity.

Table 2. Residual activities and immobilization efficiency of ADH immobilized onto epoxy functionalized CMD-MNPs, while investigating enzyme concentration.

Enzyme concentration [mg/mL]	Residual activity [%]	Immobilization efficiency [%]
0.02	87	100
0.04	42	31

An increase in ADH concentration is suggested to yield in a more active product. However, with increase of enzyme concentration to 0.04 mg/mL the residual activity of immobilized ADH-CMD-MNPs decreased. When the ADH concentration was increased from 0.02 mg/mL to 0.04 mg/mL the residual activity decreased to 42% and immobilization efficiency decreased slightly more, to 31%. Results can be observed in **Table 2**. The decrease in residual activity with increasing enzyme concentration can be attributed to the oversaturation of the enzyme over the support surface. As enzyme has an active site, it is available for

substrate binding to form a product. When enzyme molecules crowd on the support surface, due to high enzyme concentration, enzyme molecules tend to overlap each other. That overlapping leads to inaccessibility of enzyme molecules' active sites, therefore can not be bind with the substrate. As a consequence of this inaccessibility, the product can not be formed, which is expressed as reduced enzyme activity or denaturation of immobilized enzyme.^{39–42}

3. 3. Characterization

3. 3. 1. FTIR, SEM, DLS

Present peaks from FT-IR spectra of CMD-MNPs, ADH-CMD-MNPs and free ADH are presented in **Table 3**. ADH enzyme complex in ADH-CMD-MNPs shows characteristic absorption peaks at 1330 cm⁻¹, 1640 cm⁻¹ and 1450 cm⁻¹ which can also be observed in the free ADH spectra, exhibiting characteristic frequencies of ADH complex at 1640 cm⁻¹ and 1390 cm⁻¹. The symmetric ring stretching frequency of the epoxy ring around 813, 921, and 1269 cm⁻¹ were presented, indicating the existence of epoxy group on epoxy functionalized CMD-MNPs. The absorption peaks at 569 cm⁻¹ and 682 cm⁻¹ belong to the stretching vibration modes of Fe–O bond of synthesized MNPs. Characteristic adsorption peaks are shown at 1010 cm⁻¹, which corresponds to CMD νC–O vibrations, while the broad absorption peak at 3408 cm⁻¹ corresponds to the characteristic νO–H stretching and δO–H deformation modes of CMD hydroxyl groups, also CMD carboxyl groups are represented in absorption peak at 1642 cm⁻¹. FT-IR spectra is available in Supplementary Material 1.

The morphology of epoxy functionalized CMD-MNPs with immobilized ADH was investigated by SEM. **Figure 3** shows SEM images of CMD-MNPs and epoxy functionalized ADH-CMD-MNPs. It is evident that CMD-MNPs and ADH-CMD-MNPs are spherical in shape and monodispersed. However, before immobilization of ADH, CMD-MNPs had more uniform size, which was in average 28 nm, as can be observed in our previous

Table 3. Peaks from FT-IR spectra, present in soluble ADH, CMD-MNPs and ADH-CMD-MNPs.

Wavenumber [cm ⁻¹]	Functional group	Soluble ADH	CMD-MNPs	ADH-CMD-MNPs
569	Fe-O		x	x
682	Fe-O		x	x
813	epoxy		x	x
921	epoxy		x	x
1010	νC–O		x	x
1269	epoxy		x	x
1330	ADH complex	x		x
1390	ADH complex	x		x
1450	ADH complex	x		x
1640	ADH complex	x		x
3408	νO–H, δO–H		x	x

Figure 3. SEM images of CMD-MNPs (left) and ADH-CMD-MNPs (right).

research.³⁴ After immobilization CMD-MNPs are covered with a layer of enzyme due to epoxy functionalization, which allows ADH to covalently bind to CMD-MNPs. The sizes are slightly uneven and increased in diameter, ranging from 57 nm to 84 nm. Therefore, SEM images give additional evidence that ADH has been successfully bound to the surface of CMD-MNPs by covalent attachment resulting in the nano-sized product.

Zeta potential of CMD-MNPs and ADH-CMD-MNPs was measured to indicate the stability of colloidal dispersion. Both prepared CMD-MNPs and immobilized ADH-CMD-MNPs exhibit negative zeta potentials, -31.9 mV and -26.8 mV, respectively, which indicate negatively charged hydroxyl and carboxyl groups of CMD present on the surface of nanoparticles. Zeta potentials indicate that CMD-MNPs and ADH-CMD-MNPs show good dispersion in the aqueous phase. The size distribution of nanoparticles is expressed in polydispersity index (PdI). The PdI of ADH-CMD-MNPs is slightly higher, which is due to the layer of ADH, immobilized on the surface of CMD-MNPs, which can also be observed from SEM images. Because ADH-CMD-MNPs are slightly uniform in size, the PdI index increases, as well. PdI values are presented in Table 4.

Table 4. Zeta-potential and PdI obtained by DLS analysis of CMD-MNPs and ADH-CMD-MNPs. Sample

Sample	Zeta-potential (mV)	PdI
CMD-MNPs	-31.9	0.31
ADH-CMD-MNPs	-26.8	0.53

4. Conclusions

To conclude, CMD-MNPs were successfully functionalized with cross-linking of epoxide ECIH for covalent attachment of ADH. Cross-linker concentration, tempera-

ture of immobilization and enzyme concentration were successfully optimized, resulting in 90% of residual activity of immobilized ADH. Characterization of immobilized ADH onto functionalized CMD-MNPs revealed successful covalent attachment and confirmed immobilization of ADH. The resulting CMD-MNPs with immobilized ADH were spherical in shape and measured from 57 nm to 84 nm in diameter. The results indicated that epoxy functionalized CMD-MNPs are favourable for ADH immobilization.

Acknowledgment

The authors acknowledge the financial support from the Slovenian Research Agency, research core funding Nr. P2-0046 – “Separation Processes and Product Design” and research core funding Nr. J2-1725 – “Smart materials for bioapplications”, “and grant INT/Slovenia/P-16/2014”.

6. References

- de Smidt, O.; du Preez, J. C.; Albertyn, J. *FEMS Yeast Res* **2008**, *8*, 967–978. DOI:10.1111/j.1567-1364.2008.00387.x
- Raj, S. B.; Ramaswamy, S.; Plapp, B. V. *Biochemistry* **2014**, *53*, 5791–5803. DOI:10.1021/bi5006442
- Hummel, W.; Kula, M.-R. *European Journal of Biochemistry* **1989**, *184*, 1–13. DOI:10.1111/j.1432-1033.1989.tb14983.x
- Alpat, S.; Telefoncu, A. *Sensors (Basel)* **2010**, *10*, 748–764. DOI:10.3390/s100100748
- Patel, R. N. *Coordination Chemistry Reviews* **2008**, *252*, 659–701. DOI:10.1016/j.ccr.2007.10.031
- Demirköran, N.; Ekinci, E. *Acta Chim Slov* **2012**, *59*, 302–306.
- Bernal, C.; Rodríguez, K.; Martínez, R. *Biotechnology Advances* **2018**, *36*, 1470–1480. DOI:10.1016/j.biotechadv.2018.06.002
- Cowan, D. A.; Fernandez-Lafuente, R. *Enzyme and Microbial Technology* **2011**, *49*, 326–346. DOI:10.1016/j.enzmictec.2011.06.023

9. Ahmad, R.; Sardar, M. *Biochemistry & Analytical Biochemistry* **2015**, *0*, 1–8. DOI:10.4172/2161-1009.1000178
10. Stojković, G.; Znidaršič-Plazl, P. *Acta Chim Slov* **2010**, *57*, 144–149.
11. Primožič, M.; Podrepšek, G.H.; Pavlovič, I.; Škerget, M.; Knez, Ž.; Leitgeb, M. *Acta Chimica Slovenica* **2019**, *66*, 732–739. DOI:10.17344/acs.2019.5013
12. Hola, K.; Markova, Z.; Zoppellaro, G.; Tucek, J.; Zboril, R. *Biotechnology Advances* **2015**, *33*, 1162–1176. DOI:10.1016/j.biotechadv.2015.02.003
13. Tarvirdipour, S.; Vasheghani-Farahani, E.; Soleimani, M.; Bardania, H. *International Journal of Pharmaceutics* **2016**, *501*, 331–341. DOI:10.1016/j.ijpharm.2016.02.012
14. Agiotis, L.; Theodorakos, I.; Samothrakitis, S.; Papazoglou, S.; Zergioti, I.; Raptis, Y.S. *Journal of Magnetism and Magnetic Materials* **2016**, *401*, 956–964. DOI:10.1016/j.jmmm.2015.10.111
15. Masood, F. *Materials Science and Engineering: C* **2016**, *60*, 569–578. DOI:10.1016/j.msec.2015.11.067
16. Kravanja, G.; Primožič, M.; Knez, Ž.; Leitgeb, M. *Molecules* **2019**, *24*, 1–23. DOI:10.3390/molecules24101960
17. Leitgeb, M.; Heržič, K.; Podrepšek, G.H.; Hojski, A.; Crnjac, A.; Knez, Z. Toxicity of magnetic chitosan micro and nanoparticles as carriers for biologically active substances. *Acta Chim Slov* **2014**, *61*, 145–152.
18. Liu, G.; Gao, J.; Ai, H.; Chen, X. *Small* **2013**, *9*, 1533–1545. DOI:10.1002/sml.201201531
19. Markides, H.; Rotherham, M.; El Haj, A.J. *Journal of Nanomaterials* **2012**, *2012*, 1–11. DOI:10.1155/2012/614094
20. Hauser, A.K.; Mathias, R.; Anderson, K.W.; Zach Hilt, J. *Materials Chemistry and Physics* **2015**, *160*, 177–186. DOI:10.1016/j.matchemphys.2015.04.022
21. Wei, Y.; Han, B.; Hu, X.; Lin, Y.; Wang, X.; Deng, X. *Procedia Engineering* **2012**, *27*, 632–637. DOI:10.1016/j.proeng.2011.12.498
22. Agiotis, L.; Theodorakos, I.; Samothrakitis, S.; Papazoglou, S.; Zergioti, I.; Raptis, Y.S. *Journal of Magnetism and Magnetic Materials* **2016**, *401*, 956–964. DOI:10.1016/j.jcolsurfb.2012.10.030
23. Asmathunisha, N.; Kathiresan, K. *Colloids and Surfaces B: Biointerfaces* **2013**, *103*, 283–287. DOI:10.1016/j.nano.2016.01.005
24. Alcantara, D.; Lopez, S.; García-Martin, M.L.; Pozo, D. *Nanomedicine: Nanotechnology, Biology and Medicine* **2016**, *12*, 1253–1262. DOI:10.1016/j.taap.2010.08.029
25. Loh, J.W.; Yeoh, G.; Saunders, M.; Lim, L.-Y. *Toxicology and Applied Pharmacology* **2010**, *249*, 148–157. DOI:10.1021/bm0257661
26. Mateo, C.; Torres, R.; Fernández-Lorente, G.; Ortiz, C.; Fuentes, M.; Hidalgo, A.; López-Gallego, F.; Abian, O.; Palomo, J. M.; Betancor, L.; et al. *Biomacromolecules* **2003**, *4*, 772–777. DOI:10.2478/boca-2014-0001
27. Spinelli, D.; Coppi, S.; Basosi, R.; Pogni, R. *Biocatalysis* **2014**, *1*, 1–12. DOI:10.2478/boca-2014-0001.
28. National Toxicology Program Epichlorohydrin. *Rep Carcinog* **2011**, *12*, 180–183. DOI:10.1016/j.bbapap.2012.03.010
29. Petkova, G.A.; Záruba, K.; Král, V. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics* **2012**, *1824*, 792–801. DOI:10.1016/j.ijbiomac.2016.03.031
30. Jiang, X.-P.; Lu, T.-T.; Liu, C.-H.; Ling, X.-M.; Zhuang, M.-Y.; Zhang, J.-X.; Zhang, Y.-W. *Int. J. Biol. Macromol.* **2016**, *88*, 9–17. DOI:10.1016/j.jmmm.2008.08.047
31. Lei, L.; Bai, Y.; Li, Y.; Yi, L.; Yang, Y.; Xia, C. *Journal of Magnetism and Magnetic Materials* **2009**, *321*, 252–258. DOI:10.1016/j.jbej.2015.04.020
32. Babaki, M.; Yousefi, M.; Habibi, Z.; Brask, J.; Mohammadi, M. *Biochemical Engineering Journal* **2015**, *101*, 23–31. DOI:10.1007/s00449-009-0345-6
33. Bayramoglu, G.; Yilmaz, M.; Yakup Arica, M. *Bioprocess Biosyst Eng* **2010**, *33*, 439–448. DOI:10.1016/j.molcatb.2015.06.004
34. Vasić, K.; Knez, Ž.; Konstantinova, E.A.; Kokorin, A.I.; Gyergyk, S.; Leitgeb, M. *Reactive and Functional Polymers* **2020**, *148*, 1–13. DOI:10.1016/j.jbiotec.2006.01.028
35. Kägi, J.H.; Vallee, B.L. *J. Biol. Chem.* **1960**, *235*, 3188–3192. DOI:10.1016/j.jmmm.2010.08.008
36. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Analytical Biochemistry* **1976**, *72*, 248–254. DOI:10.1016/j.ijbiomac.2014.10.045
37. Bystrzejewska-Piotrowska, G.; Golimowski, J.; Urban, P.L. *Waste Management* **2009**, *29*, 2587–2595. DOI:10.1016/j.btre.2018.e00260
38. Chen, H.; Zhang, Q.; Dang, Y.; Guowei, S. *Advanc Journal of Food Science and Technology* **2013**, *5*, 932–935. DOI:10.1016/j.ijbiomac.2008.01.005
39. Jiang, D.-S.; Long, S.-Y.; Huang, J.; Xiao, H.-Y.; Zhou, J.-Y. *Biochemical Engineering Journal* **2005**, *25*, 15–23. DOI:10.1016/j.procbio.2012.01.012
40. Prousoontorn, M.H.; Pantatan, S. *J Incl Phenom Macrocycl Chem* **2007**, *57*, 39–46. DOI:10.1016/j.reactfunctpolym.2020.104481
41. Talbert, J.N.; Goddard, J.M. *Colloids and Surfaces B: Biointerfaces* **2012**, *93*, 8–19. DOI:10.1016/j.colsurfb.2012.01.003.
42. Jamil, N.; Che Man, R.; Suhaimi, S.; Md Shaarani, S.; Iffah Mohd Arshad, Z.; Kholijah Abdul Mudalip, S.; Zubaidah Sulaiman, S. *Materials Today: Proceedings* **2018**, *5*, 22036–22042. DOI:10.1016/0003-2697(76)90527-3

Povzetek

Mikrobno inhibicijo magnetnih nanodelcev (MNP) prekritih z karboksimetil dekstranom (CMD) smo preučili na dveh bakterijskih kulturah, *Escherichia coli* in *Staphylococcus aureus*. Dokazali smo inhibicijske lastnosti CMD-MNP-jev, medtem ko neprekriti MNP-ji niso imeli te lastnosti. Na CMD-MNP smo imobilizirali alkohol dehidrogenazo (ADH) iz *Saccharomyces cerevisiae*. Poleg tega smo CMD-MNP-je funkcionalizirali z zamreževalcem epiklorhidrinom (ECH) kot alternativa za ADH imobilizacijo. Primerjali smo aktivnost ADH imobilizirane na epoksi funkcionalizirane CMD-MNP-je in nefunkcionalizirane. Pod optimalnimi pogoji priprave (4% (v/v) ECH, 4 °C in 0.02 mg/mL ADH) je imobilizirana ADH ohranila 90% aktivnosti. Tako imobilizirano ADH smo okarakterizirali z FT-IR, SEM in DLS.

Except when otherwise noted, articles in this journal are published under the terms and conditions of the Creative Commons Attribution 4.0 International License